BCBálint Csörgő

Bálint Csörgő

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bálint Csörgő has a total of 278 co-authors. Here are the top co-authors by number of shared publications:

  • Balázs Papp

    Synthetic and Systems Biology Unit, Institute of Biochemistry, National Laboratory of Biotechnology, HUN-REN Biological Research Centre , Temesvári Krt. 62, Szeged 6726

    13 shared publications
  • Csaba Pál

    Synthetic and Systems Biology Unit, Institute of Biochemistry, HUN-REN Biological Research Centre, Szeged, Hungary

    12 shared publications
  • Akos Nyerges

    Department of Genetics, Harvard Medical School, Boston, MA 02115, USA

    11 shared publications
  • Gergely Fekete

    Synthetic and Systems Biology Unit, Institute of Biochemistry, Biological Research Centre, Szeged, Hungary

    7 shared publications
  • István Nagy

    Sequencing Platform, Institute of Biochemistry, Biological Research Centre, Szeged, Hungary

    7 shared publications
  • Orsolya Méhi

    Synthetic and Systems Biology Unit, Institute of Biochemistry, Biological Research Centre, Szeged, Hungary

    7 shared publications

Latest Publications

  • Open Access

    Deep-learning single-cell profiling uncovers interbacterial and drug-driven reshaping of pathogen virulence

    by Bence Bognár, Terézia Kovács, Réka Muresan, Ede Migh, Tímea Balogh, Nándor Milán Kovács, Áron Somogyi, Árpád Molnár, Bálint Csörgő, Csaba Pál, et al.

    Bacterial invasion and genotoxicity are key contributors to infectious disease progression and carcinogenesis. Yet current methods do not quantify these processes systematically and at single-cell resolution, limiting our ability to explore how interplay of virulence factors and drug effects shape pathogenicity. Here, we present MALVINA, a high-throughput deep-learning workflow integrating host-pathogen co-culture and high-content imaging to jointly measure bacterial invasion and host DNA damage. Applied to Escherichia coli isolates and human colorectal epithelial cells, we demonstrate MALVINA’s versatility by deciphering (1) strains with elevated invasive or genotoxic potential, (2) interbacterial modulation of virulence, (3) pro-virulent drug effects, (4) virulence-targeting drugs, and (5) bacterial potentiation of drug toxicity. MALVINA revealed strain-specific virulence profiles and colibactin-dependent suppression of competitors’ invasion coupled with enhanced genotoxicity. It also enabled identification of drug-induced modulation of bacterial invasion and genotoxicity, offering a new perspective for virulence-aware drug profiling. Overall, MALVINA offers an adaptable framework for dissecting pathogen-host-drug interactions.

  • Open Access

    A preclinical resistance framework discovers the virulence risks of antibiotics in development

    by Petra Szili, Márton Simon Czikkely, Zoltán Farkas, Lejla Daruka, Blanka Toldi, Eszter Kurkó, András Zoltán Vonyó, Milán Csernyák, Regina Kámán, Elvin Maharramov, et al.

    Several new antibiotics target multidrug-resistant pathogens, yet resistance is still evaluated mainly by drug-susceptibility, leaving consequences for bacterial pathogenicity poorly understood. Here, we develop a framework integrating resistance evolution, genomic surveillance and host–pathogen phenotyping to classify antibiotics by resistance potential and pathogenic consequences. Applying this framework to Klebsiella pneumoniae identified functionally distinct antibiotic candidates associated with elevated virulence risk. Resistance evolution rapidly increased virulence through clinically-relevant mutations, without direct selection for pathogenicity. Despite distinct genetic routes, resistance converged on cell-envelope rewiring. A single resistance mutation increased epithelial adhesion, intracellular colonization, macrophage immune-evasion, and tissue persistence in murine infection models, transforming K. pneumoniae into a more invasive and cytotoxic pathogen. Risk-profile analysis revealed partial decoupling of resistance and pathogenicity, with some low-resistance antibiotics yielding highly-virulent populations. These findings establish resistance-driven virulence as an underappreciated translational hazard and call for incorporating host–pathogen interactions into resistance surveillance and preclinical antibiotic development.

  • END nucleases are antiphage defence systems targeting multiple phages with modified genomes

    by Wearn-Xin Yee, Yan-Jiun Lee, Kira S. Makarova, Timothy A. Klein, Alex Wirganowicz, Andres E. Gabagat, Miaoxi Liu, Bálint Csörgő, Eugene V. Koonin, Peter R. Weigele, et al.

    Prokaryotes carry phage defence systems in ‘defence islands’ as immunity mechanisms; however, which systems are endogenously active against specific phages is often not known. Here we identify a single gene in a defence island that is necessary for a Pseudomonas aeruginosa cystic fibrosis isolate to block phages from the Pbunavirus family, which are commonly used as therapeutics. The causal defence system, here named END nucleases, has a Type IIS restriction endonuclease-like domain fused to a catalytically inactive endonuclease III (iEndoIII), which normally recognizes non-canonical bases to repair DNA in prokaryotes and eukaryotes. END nucleases exclusively antagonize the replication of modified phages, but they are agnostic to the modification, targeting up to eight distinct families of phages with modified DNA, with at least ten different known modifications beyond methylation. A small region of the iEndoIII domain is identified that dictates targeting specificity. Modified phages from the Pbunavirus and Wroclawvirus family (Pa5Oct-like) of jumbo phages encode direct-binding END nuclease inhibitors. This work identifies a broad modification-dependent restriction endonuclease and cognate inhibitors that can fortify phage outcomes.


  • Open Access

    END nucleases: Antiphage defense systems targeting multiple hypermodified phage genomes

    by Wearn-Xin Yee, Yan-Jiun Lee, Timothy A. Klein, Alex Wirganowicz, Andres E. Gabagat, Bálint Csörgő, Kira S. Makarova, Eugene V. Koonin, Peter R. Weigele, Joseph Bondy-Denomy

    Prokaryotes carry clusters of phage defense systems in “defense islands” that have been extensively exploited bioinformatically and experimentally for discovery of immune functions. However, little effort has been dedicated to determining which specific system(s) within defense islands limit lytic phage reproduction in clinical bacterial strains. Here, we employed the CRISPR-based Cascade-Cas3 system to delete defense islands in a Pseudomonas aeruginosa clinical isolate to identify mechanisms of lytic phage antagonism. Deletion of one island in a cystic fibrosis-derived clinical isolate sensitized the strain to phages from the Pbunavirus family, which are commonly used as therapeutics. The causal defense system is a Type IIS restriction endonuclease-like protein (END PaCF1 ), common in Pseudomonads, however it lacks an associated methyltransferase typical Type IIS R-M systems. END PaCF1 protects bacteria against phages with hypermodified DNA and is surprisingly agnostic to the specific structure of the modification, which is unlike typical type IV restriction endonucleases. In END PaCF1 , the endonuclease domain is fused to a catalytically inactive Endonuclease III (iEndoIII), a domain that recognizes non-canonical bases to repair DNA in prokaryotes and eukaryotes. We therefore propose that nucleases containing an i En doIII d omain ( END nucleases) can sense diverse DNA hypermodifications. Our findings reveal modularity of the sensing and cleavage domains, as expected of a modification-dependent endonucleases. We further show that some hypermodified phages, including Pbunavirus family members and Wrowclawvirus family (Pa5oct-like) of jumbo phages, encode END nuclease inhibitors that directly bind to the nuclease, likely via the iEndoIII domain. These inhibitors are necessary for Pbunavirus to plaque on clinical isolates and sufficient to enable other hypermodified phages to plaque in the presence of this defense system.


  • Antibiotic candidates for Gram-positive bacterial infections induce multidrug resistance

    by Ana Martins, Fanni Judák, Zoltán Farkas, Petra Szili, Gábor Grézal, Bálint Csörgő, Márton Simon Czikkely, Elvin Maharramov, Lejla Daruka, Réka Spohn, et al.

    Several antibiotic candidates are in development against Gram-positive bacterial pathogens, but their long-term utility is unclear. To investigate this issue, we studied the laboratory evolution of resistance to antibiotics that have not yet reached the market. We found that, with the exception of compound SCH79797, antibiotic resistance generally readily evolves in Staphylococcus aureus . Cross-resistance was detected between such candidates and antibiotics currently in clinical use, including vancomycin, daptomycin, and the promising antibiotic candidate teixobactin. These patterns were driven by overlapping molecular mechanisms through mutations in regulatory systems. In particular, teixobactin-resistant bacteria displayed clinically relevant multidrug resistance and retained their virulence in an invertebrate infection model, raising concerns. More generally, we demonstrate that putative resistance mutations against candidate antibiotics are already present in natural bacterial populations. Therefore, antibiotic resistance in nature may evolve readily from the selection of preexisting genetic variants. Our work highlights the importance of predicting future evolution of resistance to antibiotic candidates at an early stage of drug development.


  • Open Access

    A new family of bacterial ribosome hibernation factors

    by Karla Helena-Bueno, Mariia Yu. Rybak, Chinenye L. Ekemezie, Rudi Sullivan, Charlotte R. Brown, Charlotte Dingwall, Arnaud Baslé, Claudia Schneider, James P. R. Connolly, James N. Blaza, et al.

    To conserve energy during starvation and stress, many organisms use hibernation factor proteins to inhibit protein synthesis and protect their ribosomes from damage1,2. In bacteria, two families of hibernation factors have been described, but the low conservation of these proteins and the huge diversity of species, habitats and environmental stressors have confounded their discovery3–6. Here, by combining cryogenic electron microscopy, genetics and biochemistry, we identify Balon, a new hibernation factor in the cold-adapted bacterium Psychrobacter urativorans. We show that Balon is a distant homologue of the archaeo-eukaryotic translation factor aeRF1 and is found in 20% of representative bacteria. During cold shock or stationary phase, Balon occupies the ribosomal A site in both vacant and actively translating ribosomes in complex with EF-Tu, highlighting an unexpected role for EF-Tu in the cellular stress response. Unlike typical A-site substrates, Balon binds to ribosomes in an mRNA-independent manner, initiating a new mode of ribosome hibernation that can commence while ribosomes are still engaged in protein synthesis. Our work suggests that Balon–EF-Tu-regulated ribosome hibernation is a ubiquitous bacterial stress-response mechanism, and we demonstrate that putative Balon homologues in Mycobacteria bind to ribosomes in a similar fashion. This finding calls for a revision of the current model of ribosome hibernation inferred from common model organisms and holds numerous implications for how we understand and study ribosome hibernation.


  • A compact Cascade–Cas3 system for targeted genome engineering

    by Bálint Csörgő, Lina M. León, Ilea J. Chau-Ly, Alejandro Vasquez-Rifo, Joel D. Berry, Caroline Mahendra, Emily D. Crawford, Jennifer D. Lewis, Joseph Bondy-Denomy

    CRISPR–Cas technologies have enabled programmable gene editing in eukaryotes and prokaryotes. However, the leading Cas9 and Cas12a enzymes are limited in their ability to make large deletions. Here, we used the processive nuclease Cas3, together with a minimal Type I-C Cascade-based system for targeted genome engineering in bacteria. DNA cleavage guided by a single CRISPR RNA generated large deletions (7–424 kilobases) in Pseudomonas aeruginosa with near-100% efficiency, while Cas9 yielded small deletions and point mutations. Cas3 generated bidirectional deletions originating from the programmed site, which was exploited to reduce the P. aeruginosa genome by 837 kb (13.5%). Large deletion boundaries were efficiently specified by a homology-directed repair template during editing with Cascade–Cas3, but not Cas9. A transferable ‘all-in-one’ vector was functional in Escherichia coli, Pseudomonas syringae and Klebsiella pneumoniae, and endogenous CRISPR–Cas use was enhanced with an ‘anti-anti-CRISPR’ strategy. P. aeruginosa Type I-C Cascade–Cas3 (PaeCas3c) facilitates rapid strain manipulation with applications in synthetic biology, genome minimization and the removal of large genomic regions.


  • Open Access

    Targeted mutagenesis of multiple chromosomal regions in microbes

    by Bálint Csörgő, Akos Nyerges, Csaba Pál


  • Anti-CRISPR protein applications: natural brakes for CRISPR-Cas technologies

    by Nicole D. Marino, Rafael Pinilla-Redondo, Bálint Csörgő, Joseph Bondy-Denomy

    Clustered, regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes, a diverse family of prokaryotic adaptive immune systems, have emerged as a biotechnological tool and therapeutic. The discovery of protein inhibitors of CRISPR-Cas systems, called anti-CRISPR (Acr) proteins, enables the development of more controllable and precise CRISPR-Cas tools. Here we discuss applications of Acr proteins for post-translational control of CRISPR-Cas systems in prokaryotic and mammalian cells, organisms and ecosystems.


  • Open Access

    Chemical-genetic profiling reveals limited cross-resistance between antimicrobial peptides with different modes of action

    by Bálint Kintses, Pramod K. Jangir, Gergely Fekete, Mónika Számel, Orsolya Méhi, Réka Spohn, Lejla Daruka, Ana Martins, Ali Hosseinnia, Alla Gagarinova, et al.

    Antimicrobial peptides (AMPs) are key effectors of the innate immune system and promising therapeutic agents. Yet, knowledge on how to design AMPs with minimal cross-resistance to human host-defense peptides remains limited. Here, we systematically assess the resistance determinants ofEscherichia coliagainst 15 different AMPs using chemical-genetics and compare to the cross-resistance spectra of laboratory-evolved AMP-resistant strains. Although generalizations about AMP resistance are common in the literature, we find that AMPs with different physicochemical properties and cellular targets vary considerably in their resistance determinants. As a consequence, cross-resistance is prevalent only between AMPs with similar modes of action. Finally, our screen reveals several genes that shape susceptibility to membrane- and intracellular-targeting AMPs in an antagonistic manner. We anticipate that chemical-genetic approaches could inform future efforts to minimize cross-resistance between therapeutic and human host AMPs.